9th Annual Biosimilars Asia 2018
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

9th Annual Biosimilars Asia 2018

15 – 17 May 2018, Hilton Shanghai Hongqiao Hotel, China

Book Now Register Your Interest

EARLY BIRD RATE EXPIRES 16 MARCH 2018 – SAVE UP TO USD200/CNY1000. 早鸟优惠价截止3月16日
LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

The global biosimilars market is expected to reach $35 billion by 2030. Their uptake though faces considerable challenges in context to regulatory uncertainty, production complexity, interchangeability and competition. At IBC Asia’s 9th Annual Biosimilars Asia, top industry players will come together to explore tactics for overcoming hurdles unique to biosimilars in China, and globally. A focus on partnerships and commercial opportunities will be complemented by insights on disruptive technologies in manufacturing, commercialisation, risk management and pharma co-vigilance.

Key Highlights

  • 300+ Companies, 70+ speakers, 60+ Sessions
  • Unparalleled learning and targeted networking across three (3) co-located events
  • Assess global potential in the biosimilars market
  • Review the attractiveness of China as a continued investment destination
  • Developments in regulatory pathways and approvals in China
  • Examine advances in Innovation & Technology for Biosimilar Development
  • Optimise development strategies and production capabilities to ensure high product quality and stay ahead of competition
  • Preview latest equipment and technologies and hear from top vendors on how they are partnering with your peers

Part of

Biopharma Development & Production >>

Co-Located Events

Biosimilars Asia >>
Cell Line Development and Engineering >>
Biomanufacturing >>

agenda

9:00 am

Pall has built the capability to offer End 2 End solution for monoclonal antibody manufacturing, both in batch processing and in continuous processing. This workshop will help you to update the newest strategy to build a pilot or commercial facility for Mab manufacturing.

 

4:00 pm

End of workshop

8:00 am

Day 1 Main Conference Registration Opens and Morning Coffee

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS

9:00 am

Chairperson’s Opening Remarks

9:10 am

  • Innovation in biopharma pipelines – what can we expect
  • Recent regulatory developments – obstacle or opportunity?
  • How digitalisation of BioPharma is creating new value propositions
  • Biomanufacturing market snapshot in China
  • Biosimilars market potential – what can we achieve?
  • New trends in cell line development

9:50 am

[Industry Address] Understanding the Investment Climate in Biopharma Industry – How is Market Responding to Inflow and Outflow of Investments?

Abrar Mir, Managing Partner, Quadria Capital Investment Management Pte Ltd, Singapore

10:20 am

Transforming BioPharma with Technology and Digitalisation

Wang Honglou, CIO, livzon Pharmaceutical Group

10:50 am

Morning Networking and Refreshment Break

END OF OPENING PLENARY AND 9TH BIOSIMILARS ASIA CONFERENCE COMMENCES

11:20 am

Chairperson’s Opening Remarks

Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals

CHINA’S BIOSIMILARS MARKET

11:25 am

Changing Landscape of Global Biosimilars Market and What it Means for China?

Dr. Christopher J. Hickey, Senior Director Government Affairs, Market Access & Communications, Pfizer

11:45 am

Kerry Inc. Case Study on latest Biosimilars Works

Senior Representative, Kerry Inc., U.S.,

12:30 pm

Networking Lunch

1:30 pm

China Market Insight: Market Growth and Opportunities in Therapeutic Biosimilars

Jiang Junjun, Assistant Director, WuXi Biologics

2:00 pm

Managing Costs and Technology Adoption in Biosimilar Development

Senior Representative, Syneos Health,

3:00 pm

Afternoon Networking & Refreshment Break

3:30 pm

Biosimilars Development in China: Challenges in Bevacizumab Clinical Trial Design

Dr. Jacqueline Ming Liu, Vice President, TOT Biopharma, China

QUALITY AND SIMILARITY ASSESSMENT

4:00 pm

Biosimilar Clinical Materials: Changes and Comparability

Dr Qiwei Wu, Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma

4:35 pm

Fireside Chat: Analytical and Quality Assessment of Biosimilars

Dr Amy Hong Que, Vice President - Quality, Innovent Biologics

5:10 pm

Biological Products Development to Meet International Quality Standards

Dr. Li Shi, Chief Executive Officer, Shanghai Zerun Biotech Co. Ltd

5:45 pm

Chairperson’s Summary and End of Main Conference Day One followed by Networking Cocktail

8:55 am

Day 2 Main Conference

9:00 am

Chairperson’s Opening Remarks

9:10 am

Opening Address: Key Learnings from a Global Perspective How to Unlock the Full Potential of Biosimiliars - Learnings from EU on Access and Procurement

Prof. Dr. Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

9:40 am

Case Study: Global Development Strategy on Biosimilars: How to Win in the International Space

Pearl Fong, Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan

10:10 am

Biopharma’s Case Study: Perspective on Biosimilars Market Development, and China Market Potential and Partnerships

Bryan Kim, Vice President of Business Development, Samsung Bioepis, Korea

10:40 am

Morning Networking & Refreshment Break

SAFETY AND EFFICACY

11:10 am

Clinical Operations and Affairs Study, Safety, Efficacy and Risk

Dr. Xin Zhang, Head of Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China

11:40 am

Pharmacovigilance of Biologics and Biosimilars: Manufacturing, Branding, Post Approval Surveillance for Immunogenicity and Evolving Guidelines

Sunit Maity, Director, Product Development, Zumutor Biologics, India

12:10 pm

Networking Lunch

COMMERCIALISATION OF BIOSIMILARS

1:10 pm

  • Partnership and collaboration models
  • Potential markets for partnerships
  • What are the opportunities for outlicensing

1:50 pm

Establishing Product Development Partnerships

Mitul Agarwal, General Manager - Business Development & Licensing, Intas Pharmaceuticals, India

2:30 pm

Commercialization Practicality: CFDA’s Requirement on Biosimilar’s Clinical Trial Application

Eric Liu, China Biosimilars Regulation Publishing Manager, Pfizer

3:05 pm

  • Incentives, challenges and opportunities in the use of technology

For speaking opportunity, please contact Sheralin.SeeKaiLi@ibcasia.com.sg

3:40 pm

Afternoon Networking and Refreshment Break

BIOPHARMA DEVELOPMENT & PRODUCTION 2018 CLOSING PLENARY SESSIONS

4:20 pm

  • Enabling drivers of innovation in China
  • Consolidation of local players
  • Shifting investment from manufacturing focus to innovative portfolios
  • Adopting technologies that enable the potential in manufacturing, cell development and similarity
  • Attracting the right talent

5:00 pm

Chairperson’s Summary of the Day and End of Conference

pricing

Packages Price
Group Rate (4 or more delegates)US $676Early Bird
Group Rate (2 or more delegates)US $752Early Bird
2 Day ConferenceUS $977US $827Early BirdEarly Bird
Extras Price
Pre Conference Workshop US $150
Packages Price
Group Rate (4 or more delegates)US $1295Early Bird
Group Rate (2 or more delegates)US $1495Early Bird
2 Day ConferenceUS $1895US $1695Early BirdEarly Bird
Extras Price
Pre Conference Workshop US $300
  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

speakers

Noel Rob

Business Development Manager, Pall Life Sciences

Xu Wei

Vice President, Manufacturing , Innovent Biologics

Abrar Mir

Managing Partner, Quadria Capital Investment Management Pte Ltd, Singapore

Wang Honglou

CIO, livzon Pharmaceutical Group

Dr. Ming Wang

President and Chief Executive Officer, Phanes Biopharmaceuticals

Dr. Christopher J. Hickey

Senior Director Government Affairs, Market Access & Communications, Pfizer

Senior Representative, Kerry Inc., U.S.

Dr. Scott Liu

President and CEO, Shanghai Henlius Biotech Inc.

Jiang Junjun

Assistant Director, WuXi Biologics

Senior Representative, Syneos Health

Wen Yong

Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu Aosaikang Pharmaceutical Co Ltd, China

Dr. Jacqueline Ming Liu

Vice President, TOT Biopharma, China

Dr Qiwei Wu

Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma

Dr Amy Hong Que

Vice President - Quality, Innovent Biologics

Dr. Li Shi

Chief Executive Officer, Shanghai Zerun Biotech Co. Ltd

Prof. Dr. Florian Turk

Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

Pearl Fong

Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan

Bryan Kim

Vice President of Business Development, Samsung Bioepis, Korea

Dr. Xin Zhang

Head of Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China

Sunit Maity

Director, Product Development, Zumutor Biologics, India

MinSeob Lee

Team Leader of R&D CMC/PM, Celltrion R&D, Korea

Mitul Agarwal

General Manager - Business Development & Licensing, Intas Pharmaceuticals, India

Eric Liu

China Biosimilars Regulation Publishing Manager, Pfizer

Bo Qi

M.Sc. Vice President Head of CMC General Manager, Generon Beijing

Alvin Luk

Senior Vice President and Chief Medical Officer - Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China

when & where

15 - 17 May 2018

Hilton Shanghai Hongqiao
No. 1116 Hong Song East Rd, Shanghai, 201103, China
Tel: +86-21-3323 6666

contact

Still have a question?

Speaking Opportunities
Sheralin See
+65-6508 2442
 
sheralin.seekaili@ibcasia.com.sg

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489

Yvonne.Leong@ibcasia.com.sg

Media & Association Partnership Opportunities
June Tan
+65 6508 2465
June.Tan@ibcasia.com.sg

sponsors

exhibitors

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more